Canada Pension Plan Investment Board has pledged up to $20m for the Varian Medical and Johnson & Johnson-backed oncology drug developer.

Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceutical drug developer backed by corporates Varian Medical Systems and Johnson & Johnson, secured up to $20m from Canada Pension Plan Investment Board yesterday. Fusion is working on cancer treatments that will attach alpha radioactive particles to solid tumour cells to combat the disease without damaging healthy tissue. The company‚Äôs…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.